PDCD1 and non-small cell lung carcinoma: A recent phase 1 trial (UMIN000017854) tested PD1 Ab (nivolumab) in combination with bezafibrate, a ligand for PGC1α coactivator-bound PPARα which already acted synergistically with PD1 blockage in mice, in patients with advanced non-small-cell lung cancer [108].